NCIt definition : A humanized agonistic immunoglobulin G4 (IgG4) monoclonal antibody targeting the costimulatory
receptor CD137 (4-1BB; tumor necrosis factor receptor superfamily member 9; TNFRSF9),
with potential immunostimulating and antineoplastic activities. Upon administration,
evunzekibart targets and binds to CD137 expressed on a variety of leukocyte subsets
including activated T-lymphocytes and natural killer (NK) cells, and CD137 is activated
upon crosslinking to Fc-gamma receptors (FcgRs) on macrophages. This enhances CD137-mediated
signaling, induces cytotoxic T-lymphocyte (CTL) proliferation, cytokine production
and promotes a CTL-mediated anti-tumor immune response as well as induces NK-mediated
tumor cell killing and suppresses the immunosuppressive activity of T-regulatory cells
(Tregs). CD137, a surface glycoprotein of the tumor necrosis factor receptor superfamily,
is an inducible costimulatory receptor that plays a key role in T-cell proliferation,
survival and cytolytic activity. 4-1BB and FcgRs are both highly expressed in the
tumor environment (TME) while their co-expression in non-tumor tissues is low. This
may prevent systemic adverse effects.;
UNII : AKZ8CT8FMF;
CAS number : 2639688-77-8; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2639688-77-8
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;